Market Research Logo

Global Guide of Coming Off-patent Agrochemical Active Ingredients

Global Guide of Coming Off-patent Agrochemical Active Ingredients

Penoxsulam, developed and produced by Dow AgroSciences LLC (Dow AgroSciences), is a trizolopyrimidine herbicide applied in paddy fields with the widest herbicidal spectrum. It has great effect not only on aquatic weeds but also on barnyard grass which has resistance to herbicides like quinclorac, propanil and sulfonylurea.

Penoxsulam was registered in U.S. Environmental Protection Agency in 2004; later in 2005, it got promoted and applied in paddy fields in the southern US in 2005.

In 2006, penoxsulam was used in Spain, Brazil, Columbia, South Korea and Thailand.

In 2007, it was registered in Japan and China. In 2009, penoxsulam finally entered the Chinese market.
After years of development, penoxsulam enjoys a very potential future in the market, stated Chen Zaoqun, chief editor of Herbicide China News, CCM.

In fact, when penoxsulam first came into the market, the global sales volume was less than USD10 million, but in 2009, the sales volumes reached USD110 million. In 2013, the sales volume climbed to about USD225 million.

Penoxsulam also has a great performance in weed control in non-agriculture market such as in lawns and in orchards. In 2013, the sale volume of penoxsulam applied in non-agriculture market reached about USD140 million, which surpassed that of those applied in paddy fields, USD110 million.

Currently, most of the penoxsulam is applied on paddy fields and the paddy cultivation countries are mainly in Asia-Pacific and East Africa. Those markets belong to middle- and low-end market; thus, it is not difficult for enterprises to register penoxsulam products.
Penoxsulam’ great effect in weeds control makes it be needed in the market and it would be consumed most in Asia-Pacific in the next five years, Chen commented.

Besides, according to CCM's research, there is no substitute product for penoxsulam; thus, penoxsulam would be the key product in weeds control in paddy fields.

If you are interested in finding out the information on coming off-patent agrochemical active ingredients in different countries, you could have a look at our report: Global Guide of Coming Off-patent Agrochemical Active Ingredients.

In this report, you will be able to find the profiles of 36 active ingredients (11 herbicides, 8 insecticides, 17 fungicides) whose patents had been or will be expired during 2015-2020. Each profile of the agrochemical active ingredients includes basic information, history, synthesis route, application, physical & safety data, patent information and registration information in 15 target countries (Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Greece, the Netherlands, South Africa, Switzerland and Uruguay).

Every client could directly talk to our research team after choosing our report.


Executive summary
Methodology and scope
1 Profiles of coming off-patent herbicides
1.1 Flucetosulfuron
1.2 Flufenpyr-ethyl
1.3 Foramsulfuron
1.4 Metamifop
1.5 Orthosulfamuron
1.6 Penoxsulam
1.7 Pinoxaden
1.8 Propoxycarbazone
1.9 Tembotrione
1.10 Thiencarbazone-methyl
1.11 Topramezone
2 Profiles of coming off-patent insecticides
2.1 Bistrifluron
2.2 Clothianidin
2.3 Ethiprole
2.4 Flubendiamide
2.5 Metofluthrin
2.6 Pyridalyl
2.7 Pyrifluquinazon
2.8 Spirotetramat
3 Profiles of coming off-patent fungicides
3.1 Amisulbrom
3.2 Benalaxyl-M
3.3 Benthiavalicarb-isopropyl
3.4 Cyflufenamid
3.5 Dimoxystrobin
3.6 Fenpyrazamine
3.7 Fluopicolide
3.8 Fluoxastrobin
3.9 Isotianil
3.10 Metalaxyl-M
3.11 Metrafenone
3.12 Orysastrobin
3.13 Penthiopyrad
3.14 Prothioconazole
3.15 Pyraclostrobin
3.16 Silthiofam
3.17 Valifenalate
LIST OF TABLES
Table 1.1-1 Patent information of flucetosulfuron in some countries/regions, as of Aug. 2016
Table 1.1-2 Registration information of flucetosulfuron in China, as of Aug. 2016
Table 1.2-1 Patent information of flufenpyr-ethyl in some countries/regions, as of Aug. 2016
Table 1.3-1 Patent information of foramsulfuron in some countries/regions, as of Aug. 2016
Table 1.3-2 Registration information of foramsulfuron in Argentina, as of Aug. 2016
Table 1.3-3 Registration information of foramsulfuron in Denmark, as of Aug. 2016
Table 1.3-4 Registration information of foramsulfuron in Australia, as of Aug. 2016
Table 1.3-5 Registration information of foramsulfuron in Belgium, as of Aug. 2016
Table 1.3-6 Registration information of foramsulfuron in Canada, as of Aug. 2016
Table 1.3-7 Registration information of foramsulfuron in Chile, as of Aug. 2016
Table 1.3-8 Registration information of foramsulfuron in France, as of Aug. 2016
Table 1.3-9 Registration information of foramsulfuron in Greece, as of Aug. 2016
Table 1.3-10 Registration information of foramsulfuron in the Netherlands, as of Aug. 2016
Table 1.3-11 Registration information of foramsulfuron in Switzerland, as of Aug. 2016
Table 1.3-12 Registration information of foramsulfuron in Uruguay, as of Aug. 2016
Table 1.4-1 Patent information of metamifop in some countries/regions, as of Aug. 2016
Table 1.4-2 Registration information of metamifop in China, as of Aug. 2016
Table 1.4-3 Registration information of metamifop in Uruguay, as of Aug. 2016
Table 1.5-1 Patent information of orthosulfamuron in some countries/regions, as of Aug. 2016
Table 1.5-2 Registration information of orthosulfamuron in China, as of Aug. 2016
Table 1.6-1 Patent information of penoxsulam in some countries/regions, as of Aug. 2016
Table 1.6-2 Registration information of penoxsulam in Argentina, as of Aug. 2016
Table 1.6-3 Registration information of penoxsulam in Brazil, as of Aug. 2016
Table 1.6-4 Registration information of penoxsulam in Chile, as of Aug. 2016
Table 1.6-5 Registration information of penoxsulam in China, as of Aug. 2016
Table 1.6-6 Registration information of penoxsulam in France, as of Aug. 2016
Table 1.6-7 Registration information of penoxsulam in Greece, as of Aug. 2016
Table 1.6-8 Registration information of penoxsulam in Switzerland, as of Aug. 2016
Table 1.6-9 Registration information of penoxsulam in Uruguay, as of Aug. 2016
Table 1.7-1 Patent information of pinoxaden in some countries/regions, as of Aug. 2016
Table 1.7-2 Registration information of pinoxaden in Argentina, as of Aug. 2016
Table 1.7-3 Registration information of pinoxaden in Denmark, as of Aug. 2016
Table 1.7-4 Registration information of pinoxaden in South Africa, as of Aug. 2016
Table 1.7-5 Registration information of pinoxaden in Australia, as of Aug. 2016
Table 1.7-6 Registration information of pinoxaden in Belgium, as of Aug. 2016
Table 1.7-7 Registration information of pinoxaden in Canada, as of Aug. 2016
Table 1.7-8 Registration information of pinoxaden in Chile, as of Aug. 2016
Table 1.7-9 Registration information of pinoxaden in China, as of Aug. 2016
Table 1.7-10 Registration information of pinoxaden in Finland, as of Aug. 2016
Table 1.7-11 Registration information of pinoxaden in France, as of Aug. 2016
Table 1.7-12 Registration iunformation of pinoxaden in Greece, as of Aug. 2016
Table 1.7-13 Registration information of pinoxaden in the Netherlands, as of Aug. 2016
Table 1.7-14 Registration information of pinoxaden in Switzerland, as of Aug. 2016
Table 1.7-15 Registration information of pinoxaden in Uruguay, as of Aug. 2016
Table 1.8-1 Patent information of propoxycarbazone in some countries/regions, as of Aug. 2016
Table 1.8-2 Registration information of propoxycarbazone in Belgium, as of Aug. 2016
Table 1.8-3 Registration information of propoxycarbazone in Denmark, as of Aug. 2016
Table 1.8-4 Registration information of propoxycarbazone in Finland, as of Aug. 2016
Table 1.8-5 Registration information of propoxycarbazone in France, as of Aug. 2016
Table 1.8-6 Registration information of propoxycarbazone in Greece, as of Aug. 2016
Table 1.8-7 Registration information of propoxycarbazone in Canada, as of Aug. 2016
Table 1.9-1 Patent information of tembotrione in some countries/regions, as of Aug. 2016
Table 1.9-2 Registration information of tembotrione in Belgium, as of Aug. 2016
Table 1.9-3 Registration information of tembotrione in South Africa, as of Aug. 2016
Table 1.9-4 Registration information of tembotrione in Canada, as of Aug. 2016
Table 1.9-5 Registration information of tembotrione in Chile, as of Aug. 2016
Table 1.9-6 Registration information of tembotrione in France, as of Aug. 2016
Table 1.9-7 Registration information of tembotrione in Greece, as of Aug. 2016
Table 1.9-8 Registration information of tembotrione in the Netherlands, as of Aug. 2016
Table 1.9-9 Registration information of tembotrione in Switzerland, as of Aug. 2016
Table 1.10-1 Patent information of thiencarbazone-methyl in some countries/regions, as of Aug. 2016
Table 1.10-2 Registration information of thiencarbazone-methyl in Belgium, as of Aug. 2016
Table 1.10-3 Registration information of thiencarbazone-methyl in Canada, as of Aug. 2016
Table 1.10-4 Registration information of thiencarbazone-methyl in France, as of Aug. 2016
Table 1.10-5 Registration information of thiencarbazone-methyl in Greece, as of Aug. 2016
Table 1.10-6 Registration information of thiencarbazone-methyl in Switzerland, as of Aug. 2016
Table 1.10-7 Registration information of thiencarbazone-methyl in the Netherlands, as of Aug. 2016
Table 1.10-8 Registration information of thiencarbazone-methyl in Uruguay, as of Aug. 2016
Table 1.10-9 Registration information of thiencarbazone-methyl in China, as of Aug. 2016
Table 1.11-1 Patent information of topramezone in some countries/regions, as of Aug. 2016
Table 1.11-2 Registration information of topramezone in Argentina, as of Aug. 2016
Table 1.11-3 Registration information of topramezone in Belgium, as of Aug. 2016
Table 1.11-4 Registration information of topramezone in South Africa, as of Aug. 2016
Table 1.11-5 Registration information of topramezone in Canada, as of Aug. 2016
Table 1.11-6 Registration information of topramezone in Chile, as of Aug. 2016
Table 1.11-7 Registration information of topramezone in China, as of Aug. 2016
Table 1.11-8 Registration information of topramezone in Greece, as of Aug. 2016
Table 1.11-9 Registration information of topramezone in Uruguay, as of Aug. 2016
Table 1.11-10 Registration information of topramezone in the Netherlands, as of Aug. 2016
Table 2.1-1 Patent information of bistrifluron in some countries/regions, as of Aug. 2016
Table 2.1-2 Registration information of bistrifluron in Australia, as of Aug. 2016
Table 2.1-3 Registration information of bistrifluron in Argentina, as of Aug. 2016
Table 2.2-1 Patent information of clothianidin in some countries/regions, as of Aug. 2016
Table 2.2-2 Registration information of clothianidin in Argentina, as of Aug. 2016
Table 2.2-3 Registration information of clothianidin in Chile, as of Aug. 2016
Table 2.2-4 Registration information of clothianidin in Denmark, as of Aug. 2016
Table 2.2-5 Registration information of clothianidin in South Africa, as of Aug. 2016
Table 2.2-6 Registration information of clothianidin in Australia, as of Aug. 2016
Table 2.2-7 Registration information of clothianidin in Belgium, as of Aug. 2016
Table 2.2-8 Registration information of clothianidin in Brazil, as of Aug. 2016
Table 2.2-9 Registration information of clothianidin in Canada, as of Aug. 2016
Table 2.2-10 Registration information of clothianidin in China, as of Aug. 2016
Table 2.2-11 Registration information of clothianidin in Finland, as of Aug. 2016
Table 2.2-12 Registration information of clothianidin in Greece, as of Aug. 2016
Table 2.2-13 Registration information of clothianidin in the Netherlands, as of Aug. 2016
Table 2.2-14 Registration information of clothianidin in Switzerland, as of Aug. 2016
Table 2.2-15 Registration information of clothianidin in Uruguay, as of Aug. 2016
Table 2.2-16 Registration information of clothianidin in France, as of Aug. 2016
Table 2.3-1 Patent information of ethiprole in some countries/regions, as of Aug. 2016
Table 2.3-2 Registration information of ethiprole in China, as of Aug. 2016
Table 2.4-1 Patent information of flubendiamide in some countries/regions, as of Aug. 2016
Table 2.4-2 Registration information of flubendiamide in Argentina, as of Aug. 2016
Table 2.4-3 Registration information of flubendiamide in Australia, as of Aug. 2016
Table 2.4-4 Registration information of flubendiamide in South Africa, as of Aug. 2016
Table 2.4-5 Registration information of flubendiamide in Chile, as of Aug. 2016
Table 2.4-6 Registration information of flubendiamide in China, as of Aug. 2016
Table 2.4-7 Registration information of flubendiamide in Greece, as of Aug. 2016
Table 2.4-8 Registration information of flubendiamide in the Netherlands, as of Aug. 2016
Table 2.4-9 Registration information of flubendiamide in Uruguay, as of Aug. 2016
Table 2.4-10 Registration information of flubendiamide in Brazil, as of Aug. 2016
Table 2.5-1 Patent information of metofluthrin in some countries/regions, as of Aug. 2016
Table 2.5-2 Registration information of metofluthrin in Australia, as of Aug. 2016
Table 2.5-3 Registration information of metofluthrin in Canada, as of Aug. 2016
Table 2.5-4 Registration information of metofluthrin in China, as of Aug. 2016
Table 2.5-5 Registration information of metofluthrin in the Netherlands, as of Aug. 2016
Table 2.6-1 Patent information of pyridalyl in some countries/regions, as of Aug. 2016
Table 2.6-2 Registration information of pyridalyl in China, as of Aug. 2016
Table 2.6-3 Registration information of pyridalyl in South Africa, as of Aug. 2016
Table 2.6-4 Registration information of pyridalyl in the Netherlands, as of Aug. 2016
Table 2.7-1 Patent information of pyrifluquinazon in some countries/regions, as of Aug. 2016
Table 2.8-1 Patent information of spirotetramat in some countries/regions, as of Aug. 2016
Table 2.8-2 Registration information of spirotetramat in Australia, as of Aug. 2016
Table 2.8-3 Registration information of spirotetramat in Denmark, as of Aug. 2016
Table 2.8-4 Registration information of spirotetramat in South Africa, as of Aug. 2016
Table 2.8-5 Registration information of spirotetramat in Belgium, as of Aug. 2016
Table 2.8-6 Registration information of spirotetramat in Canada, as of Aug. 2016
Table 2.8-7 Registration information of spirotetramat in Chile, as of Aug. 2016
Table 2.8-8 Registration information of spirotetramat in China, as of Aug. 2016
Table 2.8-9 Registration information of spirotetramat in France, as of Aug. 2016
Table 2.8-10 Registration information of spirotetramat in Greece, as of Aug. 2016
Table 2.8-11 Registration information of spirotetramat in the Netherlands, as of Aug. 2016
Table 2.8-12 Registration information of spirotetramat in Uruguay, as of Aug. 2016
Table 2.8-13 Registration information of spirotetramat in Switzerland, as of Aug. 2016
Table 3.1-1 Patent information of amisulbrom in some countries/regions, as of Aug. 2016
Table 3.1-2 Registration information of amisulbrom in Belgium, as of Aug. 2016
Table 3.1-3 Registration information of amisulbrom in Denmark, as of Aug. 2016
Table 3.1-4 Registration information of amisulbrom in Finland, as of Aug. 2016
Table 3.1-5 Registration information of amisulbrom in the Netherlands, as of Aug. 2016
Table 3.1-6 Registration information of amisulbrom in Switzerland, as of Aug. 2016
Table 3.1-7 Registration information of amisulbrom in China, as of Aug. 2016
Table 3.1-8 Registration information of amisulbrom in Australia, as of Aug. 2016
Table 3.2-1 Patent information of benalaxyl-M in some countries/regions, as of Aug. 2016
Table 3.2-2 Registration information of benalaxyl-M in Argentina, as of Aug. 2016
Table 3.2-3 Registration information of benalaxyl-M in Australia, as of Aug. 2016
Table 3.2-4 Registration information of benalaxyl-M in Belgium, as of Aug. 2016
Table 3.2-5 Registration information of benalaxyl-M in Brazil, as of Aug. 2016
Table 3.2-6 Registration information of benalaxyl-M in Chile, as of Aug. 2016
Table 3.2-7 Registration information of benalaxyl-M in France, as of Aug. 2016
Table 3.2-8 Registration information of benalaxyl-M in Greece , as of Aug. 2016
Table 3.2-9 Registration information of benalaxyl-M in the Netherlands, as of Aug.2016
Table 3.2-10 Registration information of benalaxyl-M in Switzerland, as of Aug. 2016
Table 3.3-1 Patent information of benthiavalicarb-isopropyl in some countries/regions, as of Aug. 2016
Table 3.3-2 Registration information of benthiavalicarb-isopropyl in Belgium, as of Aug. 2016
Table 3.3-3 Registration information of benthiavalicarb-isopropyl in Denmark, as of Aug. 2016
Table 3.3-4 Registration information of benthiavalicarb-isopropyl in Greece, as of Aug. 2016
Table 3.3-5 Registration information of benthiavalicarb-isopropyl in the Netherlands, as of Aug. 2016
Table 3.3-6 Registration information of benthiavalicarb-isopropyl in Switzerland, as of Aug. 2016
Table 3.4-1 Patent information of cyflufenamid in some countries/regions, as of Aug. 2016
Table 3.4-2 Registration information of cyflufenamid in Australia, as of Aug. 2016
Table 3.4-3 Registration information of cyflufenamid in Denmark, as of Aug. 2016
Table 3.4-4 Registration information of cyflufenamid in South Africa, as of Aug. 2016
Table 3.4-5 Registration information of cyflufenamid in Belgium, as of Aug. 2016
Table 3.4-6 Registration information of cyflufenamid in Greece, as of Aug. 2016
Table 3.4-7 Registration information of cyflufenamid in the Netherlands, as of Aug. 2016
Table 3.4-8 Registration information of cyflufenamid in Switzerland, as of Aug. 2016
Table 3.4-9 Registration information of cyflufenamid in France, as of Aug. 2016
Table 3.5-1 Patent information of dimoxystrobin in some countries/regions, as of Aug. 2016
Table 3.5-2 Registration information of dimoxystrobin in Belgium, as of Aug. 2016
Table 3.5-3 Registration information of dimoxystrobin in Denmark, as of Aug. 2016
Table 3.5-4 Registration information of dimoxystrobin in France, as of Aug. 2016
Table 3.6-1 Patent information of fenpyrazamine in some countries/regions, as of Aug. 2016
Table 3.6-2 Registration information of fenpyrazamine in Australia, as of Aug. 2016
Table 3.6-3 Registration information of fenpyrazamine in Chile, as of Aug. 2016
Table 3.6-4 Registration information of fenpyrazamine in Denmark, as of Aug. 2016
Table 3.6-5 Registration information of fenpyrazamine in Belgium, as of Aug. 2016
Table 3.6-6 Registration information of fenpyrazamine in Switzerland, as of Aug. 2016
Table 3.6-7 Registration information of fenpyrazamine in France, as of Aug. 2016
Table 3.6-8 Registration information of fenpyrazamine in Greece, as of Aug. 2016
Table 3.6-9 Registration information of fenpyrazamine in the Netherlands, as of Aug. 2016
Table 3.7-1 Patent information of fluopicolide in some countries/regions, as of Aug. 2016
Table 3.7-2 Registration information of fluopicolide in Argentina, as of Aug. 2016
Table 3.7-3 Registration information of fluopicolide in Denmark, as of Aug. 2016
Table 3.7-4 Registration information of fluopicolide in South Africa, as of Aug. 2016
Table 3.7-5 Registration information of fluopicolide in Belgium, as of Aug. 2016
Table 3.7-6 Registration information of fluopicolide in Brazil, as of Aug. 2016
Table 3.7-7 Registration information of fluopicolide in Canada, as of Aug. 2016
Table 3.7-8 Registration information of fluopicolide in Chile, as of Aug. 2016
Table 3.7-9 Registration information of fluopicolide in China, as of Aug. 2016
Table 3.7-10 Registration information of fluopicolide in Finland, as of Aug. 2016
Table 3.7-11 Registration information of fluopicolide in France, as of Aug. 2016
Table 3.7-12 Registration information of fluopicolide in Greece, as of Aug. 2016
Table 3.7-13 Registration information of fluopicolide in the Netherlands, as of Aug.2016
Table 3.7-14 Registration infromation of fluopicolide in Switzerland, as of Aug. 2016
Table 3.7-15 Registration information of fluopicolide in Uruguay, as of Aug. 2016
Table 3.8-1 Patent information of fluoxastrobin in some countries/regions, as of Aug. 2016
Table 3.8-2 Registration information of fluoxastrobin in Argentina, as of Aug. 2016
Table 3.8-3 Registration information of fluoxastrobin in Belgium, as of Aug. 2016
Table 3.8-4 Registration information of fluoxastrobin in Chile, as of Aug. 2016
Table 3.8-5 Registration information of fluoxastrobin in Denmark, as of Aug. 2016
Table 3.8-6 Registration information of fluoxastrobin in Canada, as of Aug. 2016
Table 3.8-7 Registration information of fluoxastrobin in France, as of Aug. 2016
Table 3.8-8 Registration information of fluoxastrobin in the Netherlands, as of Aug. 2016
Table 3.8-9 Registration information of fluoxastrobin in Switzerland, as of Aug. 2016
Table 3.8-10 Registration information of fluoxastrobin in Uruguay, as of Aug. 2016
Table 3.8-11 Registration information of fluoxastrobin in China, as of Aug. 2016
Table 3.8-12 Registration information of fluoxastrobin in Greece, as of Aug. 2016
Table 3.9-1 Patent information of isotianil in some countries/regions, as of Aug. 2016
Table 3.10-1 Patent information of metalaxyl-M in some countries/regions, as of Aug. 2016
Table 3.10-2 Registration information of metalaxyl-M in Argentina, as of Aug. 2016
Table 3.10-3 Registration information of metalaxyl-M in Chile, as of Aug. 2016
Table 3.10-4 Registration information of metalaxyl-M in Denmark, as of Aug. 2016
Table 3.10-5 Registration information of metalaxyl-M in South Africa, as of Aug. 2016
Table 3.10-6 Registration information of metalaxyl-M in Australia, as of Aug. 2016
Table 3.10-7 Registration information of metalaxyl-M in Belgium, as of Aug. 2016
Table 3.10-8 Registration information of metalaxyl-M in Brazil, as of Aug. 2016
Table 3.10-9 Registration information of metalaxyl-M in Canada, as of Aug. 2016
Table 3.10-10 Registration information of metalaxyl-M in China, as of Aug. 2016
Table 3.10-11 Registration information of metalaxyl-M in Finland, as of Aug. 2016
Table 3.10-12 Registration information of metalaxyl-M in Greece, as of Aug. 2016
Table 3.10-13 Registration information of metalaxyl-M in the Netherlands, as of Aug. 2016
Table 3.10-14 Registration information of metalaxyl-M in Switzerland, as of Aug. 2016
Table 3.10-15 Registration information of metalaxyl-M in Uruguay, as of Aug. 2016
Table 3.10-16 Registration information of metalaxyl-M in France, as of Aug. 2016
Table 3.11-1 Patent information of metrafenone in some countries/regions, as of Aug. 2016
Table 3.11-2 Registration information of metrafenone in Australia, as of Aug. 2016
Table 3.11-3 Registration information of metrafenone in Denmark, as of Aug. 2016
Table 3.11-4 Registration information of metrafenone in South Africa, as of Aug. 2016
Table 3.11-5 Registration information of metrafenone in Belgium, as of Aug. 2016
Table 3.11-6 Registration information of metrafenone in Canada, as of Aug. 2016
Table 3.11-7 Registration information of metrafenone in Chile, as of Aug. 2016
Table 3.11-8 Registration information of metrafenone in Greece, as of Aug. 2016
Table 3.11-9 Registration information of metrafenone in Switzerland, as of Aug. 2016
Table 3.11-10 Registration information of metrafenone in China, as of Aug. 2016
Table 3.11-11 Registration information of metrafenone in the Netherlands, as of Aug. 2016
Table 3.11-12 Registration information of metrafenone in France, as of Aug. 2016
Table 3.12-1 Patent information of orysastrobin in some countries/regions, as of Aug. 2016
Table 3.13-1 Patent information of penthiopyrad in some countries/regions, as of Aug. 2016
Table 3.13-2 Registration information of penthiopyrad in Argentina, as of Aug. 2016
Table 3.13-3 Registration information of penthiopyrad in Australia, as of Aug. 2016
Table 3.13-4 Registration information of penthiopyrad in France, as of Aug. 2016
Table 3.13-5 Registration information of penthiopyrad in Canada, as of Aug. 2016
Table 3.13-6 Registration information of penthiopyrad in Greece, as of Aug. 2016
Table 3.13-7 Registration information of penthiopyrad in the Netherlands, as of Aug. 2016
Table 3.13-8 Registration information of penthiopyrad in Switzerland, as of Aug. 2016
Table 3.14-1 Patent information of prothioconazole in some countries/regions, as of Aug. 2016
Table 3.14-2 Registration information of prothioconazole in Argentina, as of Aug. 2016
Table 3.14-3 Registration information of prothioconazole in Chile, as of Aug. 2016
Table 3.14-4 Registration information of prothioconazole in Denmark, as of Aug.2016
Table 3.14-5 Registration information of prothioconazole in South Africa, as of Aug. 2016
Table 3.14-6 Registration information of prothioconazole in Australia, as of Aug. 2016
Table 3.14-7 Registration information of prothioconazole in Brazil, as of Aug. 2016
Table 3.14-8 Registration information of prothioconazole in Canada, as of Aug. 2016
Table 3.14-9 Registration information of prothioconazole in Finland, as of Aug. 2016
Table 3.14-10 Registration information of prothioconazole in France, as of Aug. 2016
Table 3.14-11 Registration information of prothioconazole in Greece, as of Aug. 2016
Table 3.14-12 Registration information of prothioconazole in the Netherlands, as of Aug. 2016
Table 3.14-13 Registration information of prothioconazole in Belgium, as of Aug. 2016
Table 3.14-14 Registration information of prothioconazole in Switzerland, as of Aug. 2016
Table 3.15-1 Patent information of pyraclostrobin in some countries/regions, as of Aug. 2016
Table 3.15-2 Registration information of pyraclostrobin in Argentina, as of Aug. 2016
Table 3.15-3 Registration information of pyraclostrobin in Chile, as of Aug. 2016
Table 3.15-4 Registration information of pyraclostrobin in South Africa, as of Aug. 2016
Table 3.15-5 Registration information of pyraclostrobin in Australia, as of Aug. 2016
Table 3.15-6 Registration information of pyraclostrobin in Belgium, as of Aug. 2016
Table 3.15-7 Registration information of pyraclostrobin in Canada, as of Aug. 2016
Table 3.15-8 Registration information of pyraclostrobin in China, as of Aug. 2016
Table 3.15-9 Registration information of pyraclostrobin in Denmark, as of Aug. 2016
Table 3.15-10 Registration information of pyraclostrobin in Finland, as of Aug. 2016
Table 3.15-11 Registration information of pyraclostrobin in France, as of Aug. 2016
Table 3.15-12 Registration information of pyraclostrobin in Greece, as of Aug. 2016
Table 3.15-13 Registration information of pyraclostrobin in the Netherlands, as of Aug. 2016
Table 3.15-14 Registration information of pyraclostrobin in South Africa, as of Aug. 2016
Table 3.15-15 Registration information of pyraclostrobin in Switzerland, as of Aug. 2016
Table 3.15-16 Registration information of pyraclostrobin in Uruguay, as of Aug. 2016
Table 3.15-17 Registration information of pyraclostrobin in Brazil, as of Aug. 2016
Table 3.16-1 Patent information of silthiofam in some countries/regions, as of Aug. 2016
Table 3.16-2 Registration information of silthiofam in Belgium, as of Aug. 2016
Table 3.16-3 Registration information of silthiofam in Chile, as of Aug. 2016
Table 3.16-4 Registration information of silthiofam in China, as of Aug. 2016
Table 3.16-5 Registration information of silthiofam in Denmark, as of Aug. 2016
Table 3.16-6 Registration information of silthiofam in the Netherlands, as of Aug. 2016
Table 3.16-7 Registration information of silthiofam in France, as of Aug. 2016
Table 3.17-1 Patent information of valifenalate in some countries/regions, as of Aug. 2016
Table 3.17-2 Registration information of valifenalate in Belgium, as of Aug. 2016
Table 3.17-3 Registration information of valifenalate in France, as of Aug. 2016
Table 3.17-4 Registration information of valifenalate in Switzerland, as of Aug. 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report